Gap junction-modifying antiarrhythmic peptides: Therapeutic potential in atrial fibrillation

Drugs of the Future

Volumn 32, Issue 3, 2007, Pages 245-260

  Haugan, Ketil ^a   Petersen, Jørgen Søberg ^a  

^a Zealand Pharma AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIARRHYTHMIC PEPTIDE; CONNEXIN 26; CONNEXIN 32; CONNEXIN 40; CONNEXIN 43; CONNEXIN 45; GAP JUNCTION PROTEIN; ROTIGAPTIDE;

DOG; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; GAP JUNCTION; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PROARRHYTHMIA; HUMAN; IN VITRO STUDY; METABOLIC STRESS; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RABBIT; REVIEW; SINUS NODE CONDUCTION VELOCITY;

EID: 34250372221     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.03.1072639     Document Type: Review

References (109)

1. Aran, A.D., Manfreda, J., Tate, R.B., Mathewson, F.A., Cuddy, T.E. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995, 98: 476-84.
2. Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V., Singer, D.E. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA - J Am Med Assoc 2001, 285: 2370-5.
3. Kannel, W.B., Abbott, R.D., Savage, D.D., McNamara, P.M. Coronary heart disease and atrial fibrillation: The Framingham Study. Am Heart J 1983, 106: 389-96.
4. Flegel, K.M., Shipley, M.J., Rose, G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987, 1: 526-9.
5. Fuster, V., Ryden, L.E., Cannom, D.S. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114: e257-354.
6. Wolbrette, D.L. Risk of proarrhythmia with class III antiarrhythmic agents: Sex-based differences and other issues. Am J Cardiol 2003, 91: 39D-44D.
7. Naccarelli, G.V., Wolbrette, D.L., Khan, M., Bhatta, L., Hynes, J., Samii, S., Luck, J. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. Am J Cardiol 2003, 91: 15D-26D.
8. Spach, M.S., Starmer, C.F. Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. Cardiovasc Res 1995, 30: 337-44.
9. Dhein, S., Tudyka, T. Therapeutic potential of antiarrhythmic peptides. Cellular coupling as a new antiarrhythmic target. Drugs 1995, 49: 851-5.
10. Van der Velden, H.M., Jongsma, H.J. Cardiac gap junctions and connexins: Their role in atrial fibrillation and potential as therapeutic targets. Cardiovasc Res 2002, 54: 270-9.
11. Nattel, S., Shiroshita-Takeshita, A., Brundel, B.J., Rivard, L. Mechanisms of atrial fibrillation: Lessons from animal models. Prog Cardiovasc Dis 2005, 48: 9-28.
12. Keren, G., Etzion, T., Sherez, J., Zelcer, A.A., Megidish, R., Miller, H.I., Laniado, S. Atrial fibrillation and atrial enlargement in patients with mitral stenosis. Am Heart J 1987, 114: 1146-55.
13. Neuberger, H.R., Schotten, U., Verheule, S., Eijsbouts, S., Blaauw, Y., van Hunnik, A., Allessie, M. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 2005, 111: 30-7.
14. Kostin, S., Klein, G., Szalay, Z., Hein, S., Bauer, E.P., Schaper, J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002, 54: 361-79.
15. Goette, A., Juenemann, G., Peters, B., Klein, H.U., Roessner, A., Huth, C., Rocken, C. Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. Cardiovasc Res 2002, 54: 390-6.
16. Allessie, M.A. Atrial electrophysiologic remodeling: Another vicious circle? J Cardiovasc Electrophysiol 1998, 9: 1378-93.
17. Sinno, H., Derakhchan, K., Libersan, D., Merhi, Y., Leung, T.K., Nattel, S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003, 107: 1930-6.
18. Korantzopoulos, P., Kolettis, T.M., Kountouris, E. et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005, 102: 321-6.
19. Carnes, C.A., Chung, M.K., Nakayama, T. et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001, 89: E32-8.
20. Zhou, S., Chang, C.M., Wu, T.J. et al. Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation. Am J Physiol Heart Circ Physiol 2002, 283: H1244-52.
21. Cox, J.L., Canavan, T.E., Schuessler, R.B. et al. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991, 101: 406-26.
22. Wang, J., Bourne, G.W., Wang, Z., Villemaire, C., Talajic, M., Nattel, S. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. Circulation 1993, 88: 1030-44.
23. Konings, K.T., Kirchhof, C.J., Smeets, J.R., Wellens, H.J., Penn, O.C., Allessie, M.A. High-density mapping of electrically induced atrial fibrillation in humans. Circulation 1994, 89: 1665-80.
24. Ohta, M., Karagueuzian, H.S., Mandel, W.J., Peter, T. Acute and chronic effects of amiodarone on delayed afterdepolarization and triggered automaticity in rabbit ventricular myocardium. Am Heart J 1987, 113: 289-96.
25. Wiener, I., Lyons, H. Amiodarone for refractory automatic atrial tachycardia: Observations on the electrophysiological actions of amiodarone. Pacing Clin Electrophysiol 1984, 7: 707-9.
26. Keane, D., Ruskin, J. Pulmonary vein isolation for atrial fibrillation. Rev Cardiovasc Med 2002, 3: 167-75.
27. Allessie, M.A., Bonke, F.I., Schopman, F.J. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: A new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 1977, 41: 9-18.
28. Wang, J., Feng, J., Nattel, S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994, 90: 2032-40.
29. Feld, G.K., Cha, Y. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide in an experimental canine model of pacing-induced atrial fibrillation. J Cardiovasc Pharmacol Ther 1997, 2: 195-203.
30. Blaauw, Y., Gogelein, H., Tieleman, R.G., van Hunnik, A., Schotten, U., Allessie, M.A. "Early" class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004, 110: 1717-24.
31. Sato, S., Yamauchi, S., Schuessler, R.B., Boineau, J.P., Matsunaga, Y., Cox, J.L. The effect of augmented atrial hypothermia on atrial refractory period, conduction, and atrial flutter/fibrillation in the canine heart. J Thorac Cardiovasc Surg 1992, 104: 297-306.
32. Hayashi, H., Wang, C., Miyauchi Y. et al. Aging-related increase to inducible atrial fibrillation in the rat model. J Cardiovasc Electrophysiol 2002, 13: 801-8.
33. Ishii, Y., Schuessler, R.B., Gaynor, S.L., Yamada, K., Fu, A.S., Boineau, J.P., Damiano, R.J. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation 2005, 111: 2881-8.
34. Sakamoto, S., Yamauchi, S., Yamashita, H. et al. Intraoperative mapping of the right atrial free wall during sinus rhythm: Variety of activation patterns and incidence of postoperative atrial fibrillation. Eur J Cardiothorac Surg 2006, 30: 132-9.
35. Tai, C.T., Chen, S.A., Tzeng, J.W., Kuo, B.I., Ding, Y.A., Chang, M.S., Shyu, L.Y. Prolonged fractionation of paced right atrial electrograms in patients with atrial flutter and fibrillation. J Am Coll Cardiol 2001, 37: 1651-7.
36. Rosiak, M., Ruta, J., Bolinska, H. Usefulness of prolonged P-wave duration on signal averaged ECG in predicting atrial fibrillation in acute myocardial infarction patients. Med Sci Monit 2003, 9: MT85-8.
37. Budeus, M., Hennersdorf, M., Perings, C., Wieneke, H., Erbel, R., Sack, S. Prediction of the recurrence of atrial fibrillation after successful cardioversion with P wave signal-averaged ECG. Ann Noninvasive Electrocardiol 2005, 10: 414-9.
38. Anyukhovsky, E.P., Sosunov, E.A., Plotnikov, A., Gainullin, R.Z., Jhang, J.S., Marboe, C.C., Rosen, M.R. Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. Cardiovasc Res 2002, 54: 462-9.
39. Kagiyama, Y., Hill, J.L., Gettes, L.S. Interaction of acidosis and increased extracellular potassium on action potential characteristics and conduction in guinea pig ventricular muscle. Circ Res 1982, 51: 614-23.
40. Dhein, S., Hammerath, S.B. Aspects of the intercellular communication in aged hearts: Effects of the gap junction uncoupler palmitoleic acid. Naunyn-Schmied Arch Pharmacol 2001, 364: 397-408.
41. Rohr, S., Kucera, J.P., Kleber, A.G. Slow conduction in cardiac tissue, I: Effects of a reduction of excitability versus a reduction of electrical coupling on microconduction. Circ Res 1998, 83: 781-94.
42. Gros, D.B., Jongsma, H.J. Connexins in mammalian heart function. Bioessays 1996, 18: 719-30.
43. Vozzi, C., Dupont, E., Coppen, S.R., Yeh, H.I., Severs, N.J. Chamber-related differences in connexin expression in the human heart. J Mol Cell Cardiol 1999, 31: 991-1003.
44. Dhein, S. Gap junction channels in the cardiovascular system: Pharmacological and physiological modulation. Trends Pharmacol Sci 1998, 19: 229-41.
45. De Mello, W.C. The role of cAMP and Ca on the modulation of junctional conductance: An integrated hypothesis. Cell Biol Int Rep 1983, 7: 1033-40.
46. Morley, G.E., Ek-Vitorin, J.F., Taffet, S.M., Delmar, M. Structure of connexin43 and its regulation by pHi. J Cardiovasc Electrophysiol 1997, 8: 939-51.
47. Li, W.E., Nagy, J.I. Connexin43 phosphorylation state and intercellular communication in cultured astrocytes following hypoxia and protein phosphatase inhibition. Eur J Neurosci 2000, 12: 2644-50.
48. Ohara, T., Qu, Z., Lee, M.H. et al. Increased vulnerability to inducible atrial fibrillation caused by partial cellular uncoupling with heptanol. Am J Physiol Heart Circ Physiol 2002, 283: H1116-22.
49. Hagendorff, A., Schumacher, B., Kirchhoff, S., Luderitz, B., Willecke, K. Conduction disturbances and increased atrial vulnerability in connexin40-deficient mice analyzed by transesophageal stimulation. Circulation 1999, 99: 1508-15.
50. Verheule, S., van Batenburg, C.A., Coenjaerts, F.E., Kirchhoff, S., Willecke, K., Jongsma, H.J. Cardiac conduction abnormalities in mice lacking the gap junction protein connexin40. J Cardiovasc Electrophysiol 1999, 10: 1380-9.
51. van der Velden, H.M., van Kempen, M.J., Wijffels, M.C., van Zijverden, M., Groenewegen, W.A., Allessie, M.A., Jongsma, H.J. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol 1998, 9: 596-607.
52. Nao, T., Ohkusa, T., Hisamatsu, Y. et al. Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm. Am J Cardiol 2003, 91: 678-83.
53. Elvan, A., Huang, X.D., Pressler, M.L., Zipes, D.P. Radiofrequency catheter ablation of the atria eliminates pacing-induced sustained atrial fibrillation and reduces connexin 43 in dogs. Circulation 1997, 96: 1675-85.
54. Wetzel, U., Boldt, A., Lauschke, J. et al. Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. Heart 2005, 91: 166-70.
55. Ohara, K., Miyauchi, Y., Ohara, T et al. Downregulation of immunodetectable atrial connexin40 in a canine model of chronic left ventricular myocardial infarction: Implications to atrial fibrillation. J Cardiovasc Pharmacol Ther 2002, 7: 89-94.
56. van der Velden, H., Ausma, J., Rook, M.B., Hellemons, A.J., van Veen, T.A., Allessie, M.A., Jongsma, H.J. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000, 46: 476-86.
57. Polontchouk, L., Haefliger, J.A., Ebelt, B. et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001, 38: 883-91.
58. Dupont, E., Ko, Y.S., Rothery, S., Coppen, S.R., Baghai, M., Haw, M., Severs, N.J. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation 2001, 103: 842-9.
59. Aonuma, S., Kohama, Y., Akai, K., Komiyama, Y., Nakajima, S., Wakabayashi, M., Makino, T. Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters. Chem Pharm Bull (Tokyo) 1980, 28: 3332-9.
60. Aonuma, S., Kohama, Y., Makino, T., Fujisawa, Y. Studies of heart. XXI. Amino acid sequence of antiarrhythmic peptide (AAP) isolated from atria. J Pharmacobiodyn 1982, 5: 40-8.
61. Argentieri, T., Cantor, E., Wiggins, J.R. Antiarrhythmic peptide has no direct cardiac actions. Experientia 1989, 45: 737-8.
62. Dhein, S., Manicone, N., Muller, A. et al. A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study. Naunyn-Schmied Arch Pharmacol 1994, 350: 174-84.
63. Muller, A., Gottwald, M., Tudyka, T., Linke, W., Klaus, W., Dhein, S. Increase in gap junction conductance by an antiarrhythmic peptide. Eur J Pharmacol 1997, 327: 65-72.
64. Kjølbye, A.L., Knudsen, C.B., Jepsen, T., Larsen, B.D., Petersen, J.S. Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): In vivo and in vitro studies. J Pharmacol Exp Ther 2003, 306: 1191-9.
65. Dhein, S., Larsen, B.D., Petersen, J.S., Mohr, F.W. Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern. Cell Commun Adhes 2003, 10: 371-8.
66. Xing, D., Kjølbye, A.L., Nielsen, M.S., Petersen, J.S., Harlow, K.W., Holstein-Rathlou, N.H., Martins, J.B. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 2003, 14: 510-20.
67. Eloff, B.C., Gilat, E., Wan, X., Rosenbaum, D.S. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: Evidence supporting a novel target for antiarrhythmic therapy. Circulation 2003, 108: 3157-63.
68. Hennan, J.K., Feldman, H.S., Swillo, R.E. et al. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Pharmacol Exp Ther 2006, 317: 236-43.
69. Haugan, K., Olsen, K.B., Hartvig, L., Petersen, J.S., Holstein-Rathlou, N.H., Hennan, J.K., Nielsen, M.S. The antiarrhythmic peptide analogue ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Electrophysiol 2005, 16: 537-45.
70. Haugan, K., Kjølbye, A.L., Hennan, J.K., Petersen, J.S. Rotigaptide (ZP123) reverts established atrial conduction velocity slowing. Cell Commun Adhes 2005; 12: 271-8.
71. Shiroshita-Takeshita, A., Sakabe, M., Haugan, K., Hennan, J.K., Nattel, S. Model-dependent effects of the gap-function conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 2007, 115: 310-8.
72. Muller, A., Schaefer, T., Linke, W., Tudyka, T., Gottwald, M., Klaus, W., Dhein, S. Actions of the antiarrhythmic peptide AAP10 on intercellular coupling. Naunyn-Schmied Arch Pharmacol 1997, 356: 76-82.
73. Jorgensen, N.R., Teilmann, S.C., Henriksen, Z. et al. The antiarrhythmic peptide analog rotigaptide (ZP123) stimulates gap junction intercellular communication in human osteoblasts and prevents decrease in femoral trabecular bone strength in ovariectomized rats. Endocrinology 2005, 146: 4745-54.
74. Guerra, J.M., Everett, T.H., Lee, K.W., Wilson, E., Olgin, J.E. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 2006, 114: 110-8.
75. Peracchia, C.J. Effects of the anesthetics heptanol, halothane and isoflurane on gap junction conductance in crayfish septate axons: A calcium- and hydrogen-independent phenomenon potentiated by caffeine and theophylline, and inhibited by 4-aminopyridine. Membr Biol 1991, 121: 67-78.
76. Hartvig, L., Christjansen, K.N., Hyttel, J., Petersen, J.S. ZP123 prevents 18a-glycyrrhetinic acid-induced inhibition of cAMP transfer. Acta Physiol Scand 2004, 181: Abst A109.
77. Xing, D., Kjolbye, A.L., Petersen, J.S., Martins, J.B. Pharmacological stimulation of cardiac gap junction coupling does not affect ischemia-induced focal ventricular tachycardia or triggered activity in dogs. Am J Physiol Heart Circ Physiol 2005, 288: H511-6.
78. Haugan, K., Miyamoto, T., Takeishi, Y., Kubota, I., Nakayama, J., Shimojo, H., Hirose, M. Rotigaptide (ZP123) improves atrial conduction slowing in chronic volume overload-induced dilated atria. Basic Clin Pharmacol Toxicol 2006, 99: 71-9.
79. Ren, Y., Zhang, C.T., Wu, J. et al. The effects of antiarrhythmic peptide AAP10 on ventricular arrhythmias in rabbits with healed myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 2006, 34: 825-8.
80. Lammers, W.J., Kirchhof, C., Bonke, F.I., Allessie, M.A. Vulnerability of rabbit atrium to reentry by hypoxia. Role of inhomogeneity in conduction and wavelength. Am J Physiol 1992, 262: H47-55.
81. Gami, A.S., Pressman, G., Caples, S.M. et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004, 110: 364-7.
82. Haugan, K., Lam, H.R., Knudsen, C.B., Petersen, J.S. Atrial fibrillation in rats induced by rapid transesophageal atrial pacing during brief episodes of asphyxia: A new in vivo model. J Cardiovasc Pharmacol 2004, 44: 125-35.
83. Verheule, S., Wilson, E., Banthia, S., Everett, T.H., Shanbhag, S., Sih, H.J., Olgin, J. Direction-dependent conduction abnormalities in a canine model of atrial fibrillation due to chronic atrial dilatation. Am J Physiol Heart Circ Physiol 2004, 287: H634-44.
84. Benjamin, E.J., Levy, D., Vaziri, S.M., D'Agostino, R.B., Belanger, A.J., Wolf, P.A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA - J Am Med Assoc 1994, 271: 840-4.
85. Takahashi, N., Atsumi, H., Nakada, S., Takeishi, Y., Tomoike, H. Alterations in the inotropic responses to forskolin and Ca2+ and reduced gene expressions of Ca2+-signaling proteins induced by chronic volume overload in rabbits. Jpn Circ J 2000, 64: 861-7.
86. Hirose, M., Takeishi, Y., Miyamoto, T., Kubota, I., Laurita, K.R., Chiba, S. Mechanism for atrial tachyarrhythmia in chronic volume overload-induced dilated atria. J Cardiovasc Electrophysiol 2005, 16: 760-9.
87. Gaspo, R., Bosch, R.F., Talajic, M., Nattel, S. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997, 96: 4027-35.
88. Yue, L., Melnyk, P., Gaspo, R., Wang, Z., Nattel, S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999, 84: 776-84.
89. Li, D., Fareh, S., Leung, T.K., Nattel, S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999, 100: 87-95.
90. Fenelon, G., Shepard, R.K., Stambler, B.S. Focal origin of atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol 2003, 14: 1093-102.
91. Okuyama, Y., Miyauchi, Y., Park, A.M. et al. High resolution mapping of the pulmonary vein and the vein of Marshall during induced atrial fibrillation and atrial tachycardia in a canine model of pacing-induced congestive heart failure. J Am Coll Cardiol 2003, 42: 348-60.
92. Sakata, K., Kurihara, H., Iwamori, K., Maki, A., Yoshino, H., Yanagisawa, A., Ishikawa, K. Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction. Am J Cardiol 1997, 80: 1522-7.
93. Wong, C.K., White, H.D., Wilcox, R.G., Criger, D.A., Califf, R.M., Topol, E.J., Ohman, E.M. Significance of atrial fibrillation during acute myocardial infarction, and its current management: Insights from the GUSTO-3 trial. Card Electrophysiol Rev 2003, 7: 201-7.
94. Garcia-Dorado, D., Theroux, P., Duran, J.M. et al. Selective inhibition of the contractile apparatus. A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion. Circulation 1992, 85: 1160-74.
95. Schlack, W., Uebing, A., Schafer, M., Bier, F., Schafer, S., Piper, H.M., Thamer, V. Regional contractile blockade at the onset of reperfusion reduces infarct size in the dog heart. Pflugers Arch 1994, 428: 134-41.
96. Sebbag, L., Verbinski, S.G., Reimer, K.A., Jennings, R.B. Protection of ischemic myocardium in dogs using intracoronary 2,3-butanedione monoxime (BDM). J Mol Cell Cardiol 2003, 35: 165-76.
97. Saltman, A.E., Aksehirli, T.O., Valiunas, V., Gaudette, G.R., Matsuyama, N., Brink, P., Krukenkamp, I.B. Gap junction uncoupling protects the heart against ischemia. J Thorac Cardiovasc Surg 2002, 124: 371-6.
98. Kanno, S., Kovacs, A., Yamada, K.A., Saffitz, J.E. Connexin43 as a determinant of myocardial infarct size following coronary occlusion in mice. J Am Coll Cardiol 2003, 41: 681-6.
99. Nattel, S. The clinical relevance of connexin gating: How to control communication in the heart. Heart Rhythm 2004, 1: 234.
100. Haugan, K., Marcussen, N., Kjølbye, A.L., Nielsen, M.S., Hennan, J.K., Petersen, J.S. Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 2006, 47: 236-42.
101. Clarke, T.C., Thomas, D., Petersen, J.S., Evans, W.H., Martins, P.E.M. The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communicatoin in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol 2006, 147: 486-95.
102. Axelsen, L.N., Stahlhut, M., Mohammed, S. et al. Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). J Mol Cell Cardiol 2006, 40: 790-8.
103. Lampe, P.D., Lau, A.F. The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol 2004, 36: 1171-86.
104. Herve, J.C., Sarrouilhe, D. Modulation of junctional communication by phosphorylation: Protein phosphatases, the missing link in the chain. Biol Cell 2002, 94: 423-32.
105. Stahlhut, M., Petersen, J.S., Hennan, J.K., Ramirez, M.T. The antiarrhythmic peptide rotigaptide (ZP123) increases connexin 43 protein expression in neonatal rat ventricular cardiomyocytes. Cell Commun Adhes 2006, 13: 21-7.
106. Kanagaratnam, P., Rothery, S., Patel, P., Severs, N.J., Peters, N.S. Relative expression of immunolocalized connexins 40 and 43 correlates with human atrial conduction properties. J Am Coll Cardiol 2002, 39: 116-23.
107. Kanagaratnam, P., Cherian, A., Stanbridge, R.D., Glenville, B., Severs, N.J., Peters, N.S. Relationship between connexins and atrial activation during human atrial fibrillation. J Cardiovasc Electrophysiol 2004, 15: 206-16.
108. Gros, D., Jarry-Guichard, T., Ten Velde, I., de Maziere, A., van Kempen, M.J., Davoust, J., Briand, J. Restricted distribution of connexin40, a gap junctional protein, in mammalian heart. Circ Res 1994, 74: 839-51.
109. Verheule, S., van Kempen, M.J., te Welscher, P.H., Kwak, B.R., Jongsma, H.J. Characterization of gap junction channels in adult rabbit atrial and ventricular myocardium.